Background & Aims: To improve prognosis in patients with hepatocellular carcinoma (HCC), the molecular mechanisms of tumor thrombus formation and metastasis must be clarified. The epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) play crucial roles in tumor invasion and metastasis. This study aimed to reveal the clinical significance of the expression of the functional CSC marker, CD13, and investigate the correlation between CD13 expression and two EMT markers, E-cadherin and vimentin. Methods: We acquired clinical samples from 86 patients with HCC that underwent radical liver resections. We performed immunohistochemistry to evaluate CD13, E-cadherin and vimentin expression. We investigated the relationships among protein expression levels, clinicopathological factors and prognosis. Results: Based on CD13 expression, patients were categorized into CD13 high (n = 30, 34.9%) and
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer deaths worldwide, particularly in East Asian countries. Liver resection is considered a radical treatment for HCC. However, the prognosis after surgery remains unsatisfactory, due to the high incidence of recurrence (1) (2) (3) . Furthermore, the presence of a portal vein tumor thrombus (PVTT) and multiple intrahepatic metastases is considered a contraindication to surgery. Many patients are diagnosed with HCC at advanced stages (4, 5) . To improve the prognosis of patients with HCC, it is necessary to clarify the molecular mechanisms of tumor thrombus formation and metastasis.
The epithelial-mesenchymal transition (EMT) plays crucial roles in developmental processes, such as neural crest and mesoderm formation during embryogenesis. The EMT has also been shown to play a key role in tumor invasion and metastasis (6) . The loss of E-cadherin is a hallmark of the EMT process, and mesenchymal markers, such as vimentin, N-cadherin and fibronectin are upregulated during EMT. The loss of E-cadherin and the upregulation of mesenchymal markers have been associated with invasiveness, metastatic potential and poor clinical outcome in several cancers, including HCC (7, 8) .
Potentially, the mechanisms underlying metastasis and therapeutic resistance might involve the presence of cancer stem cells (CSCs). CSCs comprise a sub-population of cancer cells that are capable of self-renewal, differentiation and tumorigenesis (9, 10) . CSCs are also resistant to chemotherapy and radiation therapy, and they were associated with poor prognosis in several malignancies (10) . In previous studies on HCC, the side population (SP) fraction, CD13+, CD133+, CD44+, CD90+ and epithelial cell adhesion molecules were identified as CSC markers (11) (12) (13) (14) (15) . We previously reported that CD13 was a functional CSC marker, and it regulated the levels of reactive oxygen species in HCC (15) . Recent studies have indicated that CSCs are closely correlated with the EMT (16) . Induction of the EMT modulated the CSC phenotype in breast cancer cells (17) . However, the correlation between CSC markers and the EMT has not been clarified.
In this study, we aimed to evaluate CD13 expression in HCC and determine its clinical significance. We also evaluated the correlation between CD13 expression and EMT markers, E-cadherin and vimentin.
Materials and methods

Patients and clinical samples
This study included 86 patients with HCC that underwent liver resections at Osaka University Hospital between 2003 and 2012. The clinical and pathological characteristics of these patients are summarized in Table 1 . The 86 patients comprised 65 males and 21 females, with a median age of 65.5 years (range, 39-78). Thirty nine patients had Hepatitis B virus (HBV) infections and 44 patients had hepatitis C virus (HCV) infections. Macroscopic vascular invasions were observed in 33 patients (37.2%).
Immunohistochemical staining
We performed immunohistochemical staining to detect CD13, E-cadherin and vimentin with the avidin-biotin-peroxidase complex and the Vectastain ABC kit (Vector Labs, Burlingame, CA) as described previously (18) . Briefly, formalin-fixed, paraffin-embedded, 4-μm thick sections were deparaffinized in xylene and re-hydrated in a graded ethanol series. Antigen-retrieval was performed by immersing sections in 10 mM sodium citrate buffer (pH 6.0) at 95°C for 50 min (CD13 and E-cadherin) or 40 min (vimentin). Next, sections were incubated in methanol that contained 0.1% hydrogen peroxide at room temperature for 20 min to block endogenous peroxidases. Then, sections were incubated with normal serum to block nonspecific proteins at room temperature for 20 min. Next, sections were incubated overnight at 4°C with anti-CD13 (mouse monoclonal IgG, diluted 1:250, clone 38C12, Abcam), anti-E-cadherin (rabbit polyclonal IgG, diluted 1:100, clone sc-7870, Santa Cruz Biotechnology), or anti-vimentin (mouse monoclonal IgG, diluted 1:100, clone V9, Dako), as primary antibodies. After washing three times for 5 min in phosphate-buffered saline (PBS), sections were incubated with biotinconjugated secondary antibodies (horse anti-mouse for CD13 and vimentin; goat anti-rabbit for E-cadherin). For visualization, we developed the sections in 3,3'-diaminobenzidine (DAB) solution for 3 min. All sections were counterstained with hematoxylin. Tissue samples of normal liver, normal esophageal epithelial cells and normal fibroblasts were used as positive controls for CD13, E-cadherin and vimentin, respectively. Slides processed without the primary antibodies served as negative controls.
Evaluation of immunohistochemical staining
Two investigators independently assessed and evaluated the immunohistochemically stained sections without knowledge of the corresponding clinicopathological data. When the assessment was different between the two investigates, the differences were resolved by reassessment and consensus. To evaluate the reproducibility of the immunohistochemistry assessments, we calculated the kappa values. The kappa value for the assessments of CD13, E-cadherin and vimentin were 0.923, 0.953 and 0.766, respectively. CD13 was expressed in both tumor cells and non-cancerous liver cells. Expression of CD13 was mainly detected on cell membranes, and two different expression patterns were observed in cancer cells. One was a canalicular pattern, and the other was a whole-membrane pattern ( Fig. 1A and B) . We defined CD13-positive cells as cells with whole-membrane staining. We selected 10 visual fields at 200× magnification, and we counted the number of CD13-positive cells. The CD13 high group exhibited more than five CD13-positive cells/10 fields ( Fig. 1C and D) by reference to evaluation method for mitotic count using several malignancies (19, 20) . We also evaluated a canalicular pattern staining in HCC and compared clinicopathological factors with the expression of a canalicular pattern. E-cadherin expression was considered positive when the staining intensity on tumor cell membranes was equal to or stronger than that on non-cancerous liver cells. E-cadherin positivity was assessed according to the percentage of positive staining cells out of total tumor cells. E-cadherin expression was considered preserved (E-cad (+)) when 30% or more than 30% of tumor cells showed positive E-cadherin staining. Conversely, E-cadherin expression was considered reduced (E-cad(−)) when less than 30% of tumor cells showed positive E-cadherin staining ( Fig. 1E and F) .
Vimentin staining was considered positive when it was detected either on the membrane or in the cytoplasm of tumor cells. Vimentin expression was considered positive (Vim(+)) when 5% or more than 5% of tumor cells showed positive vimentin staining. Conversely, vimentin staining was considered negative (Vim(−)) when less than 5% of tumor cells showed positive vimentin staining ( Fig. 1G and H) . The cut-offs of E-cadherin and vimentin were referred to previous reports in other cancers (21, 22) .
Univariate and multivariate analyses for overall survival and disease-free survival
Median follow up time of 86 patients is 5.51 years. In the overall survival analysis, the endpoint is defined as death from any cause. In the disease-free survival analysis, the endpoint is reached when recurrence was diagnosed. Univariate and multivariate analyses for overall survival and disease-free survival were performed using a Cox proportional hazards model. Age, sex, HBV infection, HCV infection, Child-Pugh classification, presence of liver cirrhosis, preoperative alpha fetoprotein (AFP) level, tumor size, number of tumors, macroscopic vascular invasion, growth pattern of the tumor (expansive or invasive growth), microscopic vascular invasion, microscopic intrahepatic metastasis and histological grade were submitted to univariate analyses. Only significant factors (P value less than 0.05) were submitted to the multivariate Cox proportional hazards analysis.
Prognostic implication of the combination of CD13 and vimentin expression
To examine the prognostic implication of the combination of CD13 and vimentin, we categorized into three groups depending on CD13 and vimentin expression. HCC which showed both CD13 high and vimentin(+) is defined as double positive. HCC which showed both CD13low and vimentin(−) is defined as double negative. The others, which showed either CD13 high or vimentin(+) are defined as single positive. We evaluated the overall and disease-free survival in these three groups.
CD13, E-cadherin, and vimentin in portal vein tumor thrombi
To evaluate differences in CD13, E-cadherin, and vimentin expression levels between the main tumor and its corresponding PVTT (near the main tumor and on the tip of the tumor thrombus), we examined nine patients with a PVTT in the main trunk of the portal vein. Main HCC tumor and PVTT specimens were fixed in 10% buffered formalin, embedded in paraffin and stained with hematoxylin-eosin for histological evaluations. . We also evaluated a canalicular pattern staining of CD13 in HCC. A canalicular pattern staining of CD13 was detected in 82 patients with HCC. Only four patients (4.7%) did not show canalicular pattern staining of CD13 (CD13 canalicular(−)). E-cadherin expression was detected in both the membrane and cytoplasm of tumor cells and in the membranes of non-cancerous liver cells. We classified 38 patients (44.2%) as E-cad(+). Vimentin staining was detected in endothelial cells and some lymphocytes. Cancer cells showed vimentin staining in the cytoplasm. We classified 12 patients (14.0%) as Vim(+).
Relationship between expression of CD13, E-cadherin or vimentin and clinicopathological characteristics
The relationship between whole-membrane CD13 expression and clinicopathological characteristics was analyzed ( Table 2 ). The mean tumor sizes (±SD) were 4.2 ± 2.7 cm in the CD13 low group and 6.1 ± 4.7 cm in the CD13 high group (P = 0.0491). No significant differences between these groups were noted in terms of age, gender, ChildPugh classification, liver cirrhosis, macroscopic/microscopic vascular invasion or tumor differentiation. We also compared the expression of a canalicular CD13 and clinicopathological factors in the Supplemental Table 1 . All four patients in CD13 canalicular(−) are negative of HCV infection. Two patients were categorized in ChildPugh classification B. However, there is no significant clinicopathological factors associated with expression of a canalicular pattern of CD13. The relationship between E-cadherin expression and clinicopathological characteristics is shown in Table 3 . There was no significant difference between the E-cadherin-positive and -negative groups, except for the growth pattern. In the E-cad(−) group, 12 tumors showed invasive growth, which was significantly more Values are the number of cases, the number of cases (%), or mean ± SD; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha fetoprotein; Eg, expansive growth; Ig, invasive growth. frequent than the number in the E-cad(+) group. The relationship between vimentin expression and clinicopathological characteristics is shown in Table 3 . The Vim(+) group showed high frequencies of macroscopic vascular invasion, microscopic vascular invasion, and the invasive growth pattern. The Vim(+) and Vim(−) groups were not significantly different, except in the frequency of vascular invasion and the growth pattern.
Correlation between CD13 expression and E-cadherin or vimentin expression
We detected positive vimentin staining in seven cases (23.3%) in the CD13 high group and five cases (8.9%) in the CD13 low group.
However, in this analysis, the correlation between CD13 and vimentin expression was not significant. We found no significant correlation between CD13 expression and E-cadherin expression (Table 4) .
Relationship between CD13, E-cadherin or vimentin and prognosis after surgery
The disease-free survival curves and the overall survival curves are shown in Fig. 2 . The 1-, 3-and 5-year disease-free survival rates were 40.0%, 26.7% and 13.3%, respectively, in the CD13 high group, and 61.7%, 39.8% and 31.9%, respectively, in the CD13 low group. The difference between groups was significant (P = 0.0388). The 1-, 3-and 5-year disease-free survival rates were 33.3%, 8.3% and 0%, respectively, in the vimentin-positive group and 57.3%, 38.2% and 29.4%, respectively, in the vimentin-negative group. Thus, disease-free survival was significantly shorter in the vimentinpositive group than in the vimentin-negative group (P = 0.0056). The univariate analysis for disease-free survival revealed that the Child-Pugh B, multiple tumors, the presence of microscopic intrahepatic metastasis, CD13 high expression and positive of vimentin (Vim (+)) were significant predictors of a short disease-free survival time.
In the multivariate analysis, CD13 was a marginal prognostic factor for disease-free survival (HR, 1.52; 95% CI: 0.92-2.48; P = 0.099) (Supplemental Table 2 ). The overall survival analysis showed that the 5-year survival rate was 54.7% in the CD13 high group and 73.8% in the CD13 low group. Thus, survival in the CD13 high group was significantly shorter than in the CD13 low group (P = 0.0407). The 5-year overall survival rate was 42.9% in the vimentin-positive group and 70.4% in vimentin-negative group. The overall survival time tended to be shorter in the vimentin-positive group than in the vimentin-negative group (P = 0.0770). There was no significant correlation between Values are the number of cases, the number of cases (%) or mean ± SD; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha fetoprotein; Eg, expansive growth; Ig, invasive growth. E-cadherin expression and prognosis. The univariate analysis for overall survival indicated that multiple tumors, the presence of macroscopic vascular invasion, an invasive growth pattern, the presence of microscopic vascular invasion, the presence of microscopic intrahepatic metastasis and CD13 high expression were significant predictors of a short overall survival time. The number of tumors, macroscopic vascular invasion, growth pattern and CD13 expression were submitted to the multivariate analysis. The microscopic vascular invasion and intrahepatic metastasis were excluded because these factors were strongly confounded to macroscopic vascular invasion and multiple tumors, respectively. In the multivariate analysis, the Cox regression hazard model indicated that CD13 high was an independent prognostic factor for overall survival (HR, 1.98; 95% CI: 1.02-3.84; P = 0.044) ( Table 5 ).
Prognostic implication of the combination of CD13 and vimentin expression
Disease-free survival curve and overall survival curve depending on the combination of CD13 and vimentin are shown in Fig. 3 . 
Expression of CD13, E-cadherin and vimentin in portal vein tumor thrombus
We counted the numbers of CD13-positive cells detected in 10 microscopic fields per specimen (Fig. 4A) . The median numbers of CD13-positive cells were 5, 18 and 33, in the main tumor, the root of the PVTT and the tip of the PVTT, respectively. The rates of CD13 high and Vim (+) detection gradually increased with metastasis, from the main tumor to the tip of PVTT (Fig. 4A and B) . The ratio of CD13 high and Vim(+) in the tip of PVTT was significantly higher than those in the main tumor (P = 0.0025 and P = 0.0012, respectively). The ratio of CD13 high and Vim(+) in the root of PVTT was significantly higher than those in the main tumor (P = 0.0256 and P = 0.0084, respectively).
Discussion
In this study, we evaluated the expression of CD13, a functional CSC marker, in HCC. The immunohistochemical evaluation revealed two different patterns of CD13 expression in tumors. In non-cancerous Table 4 . Comparison between different CD13 expression levels and the expression of E-cadherin or vimentin in patients with hepatocellular carcinoma
Growth patter E-cad(+) (n = 38) E-cad(−) (n = 48) P value Vim(+) (n = 12) Vim(−) (n = 74) P value liver sections, CD13 was expressed in the lateral aspects of hepatocytes and in the apical membranes of bile ducts. The lateral aspects of hepatocytes are considered bile canaliculi. Most HCC tumors (82 of 86 patients) also showed canalicular CD13 immunostaining. These results were consistent with a previous report (23) . We also found a small number of cancer cells that showed whole-membrane CD13 staining. We took this whole-membrane staining pattern as an indicator of a CD13-positive cancer cell. CD13 is also called aminopeptidase N and zinc-binding transmembrane ectopeptidase, which is expressed on various cells (24, 25) . Our previous reports suggested that CD13 was a CSC marker in HCC, and that CD13 expression increased after transcatheter arterial chemoembolization (15, 26) . CSCs are a sub-population of cancer cells capable of self-renewal, pluripotency and tumor-initiation (10) . Several cell-surface antigens have been identified as CSC markers in HCC, including CD133, CD44, CD90 and epithelial cell adhesion molecules (11) (12) (13) (14) (15) . Previous studies have evaluated associations between the expression of these CSC markers in clinical samples and clinicopathological factors. Song et al. analyzed CD133 expression in 63 tissue specimens. They revealed that CD133 expression was associated with tumor grade and stage, and it was an independent indicator of a poor prognosis (27) . However, another study suggested that CD133 expression was correlated only with capsule formation, and not with recurrence or survival (28) . Some, but not all, studies showed that the expression of a CSC marker was a poor prognostic predictor (27) (28) (29) (30) . However, no report had previously evaluated the expression of CD13 in HCC. In the present study, we grouped patients with HCC into two groups, CD13 high and CD13 low , according to the number of cells in a tumor that showed positive CD13 staining. We compared clinicopathological factors in these groups, and found that mean tumor size was significantly larger in the CD13 high group than in the CD13 low group. This finding suggested that the CSC population may be enriched in large tumors. We also found that CD13 expression was associated with recurrence and survival. Because CSCs possess tumor-initiating properties and are correlated with therapeutic resistance and recurrence, CD13-enriched tumors are expected to have high potential for malignancy.
In the present study, we also evaluated the expression of EMT markers, E-cadherin and vimentin, in HCC samples. Loss of E-cadherin is considered a hallmark of EMT, and it was associated with aggressive clinicopathological factors and a poor prognosis (31) (32) (33) . Our study revealed that E-cadherin expression levels were correlated with expansive and invasive HCC growth patterns. However, E-cadherin expression was not correlated with recurrence or survival. Previous reports showed that a loss of E-cadherin was frequently observed in larger, poorly differentiated tumors that were in advanced stages although the evaluation method of immunohistochemical staining of E-cadherin were various in the previous studies. However, the loss of E-cadherin was not an independent prognostic factor in the multivariate analysis (32) .
Vimentin is a cytoplasmic, intermediate filament protein, frequently expressed in mesenchymal cells. Vimentin expression was associated with an invasive tumor phenotype and a poor prognosis in various cancers (34, 35) . Hu et al. revealed that vimentin was significantly upregulated in metastatic HCC, compared with its expression in primary cancer sites (36) . Our study revealed that vimentin expression was associated with invasive growth and vascular invasion. Furthermore, we showed that vimentin expression was a predictor of early recurrence and short survival, consistent with previous reports (36, 37) . Recent studies have implied a correlation between EMT and CSCs (38,39). Mani et al. reported that the induction of EMT promoted the expression of stem cell markers, and isolated stemlike cells also expressed EMT phenotypes in mammary epithelial cells (16) . Tumor cells which expressed EMT related proteins also expressed stemness-related protein in HCC (40) . We also evaluated the expression of CD13, E-cadherin and vimentin in main tumors and in the roots and tips of PVTTs. HCC lesions associated with massive PVTTs exhibited high frequencies of CD13-positive and E-cadherin-deficient expression. Furthermore, the number of CD13-positive cells was enriched from the main tumor to the tip of the PVTT, and the number of vimentin-positive cells gradually increased from the main tumor to the tip of the PVTT. Hu et al. established two cell lines, one from a primary HCC and the other from its corresponding PVTT. They compared the gene expression profiles between these cell lines and detected vimentin overexpression in the cell line from the PVTT (36) . A recent report suggested that ICAM-1-related, non-coding RNA could regulate CSC properties and contributed to the development of PVTTs (41) . Our results were consistent with those findings.
The main limitation of this study was that we only used immunohistochemistry to evaluate the expression of CSC and EMT markers. A cDNA array or microRNA array analysis might have provided more information about the formation of PVTTs, the invasion process and recurrence.
In conclusion, we found that enrichment of the functional CSC marker, CD13, was correlated with early recurrence and shorter survival in patients with HCC. Our findings also suggested that the expression of vimentin and CD13 might be associated with PVTT. These results suggested that CD13 might be a potential therapeutic target for treating HCC, because the regulation of CSC and the suppression of EMT are essential for effective molecular targeting therapies.
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